Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SBPV04

Sigma-Aldrich

BCRP Human Vesicular Transport Kit

membrane based kit for Human BCRP Vesicular Transport Assays

Synonym(s):

ABCG2, Breast Cancer Resistance Protein

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352200

recombinant

expressed in human cells

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... ABCG2(9429)

General description

SOLVO Biotechnology offers ready-to-use assay kits for efflux and uptake transporters. SOLVO′s PREDIVEZ Vesicular Transport Assay Kits are suitable for efflux transporter inhibition studies. The kits are designed to test the inhibitory effect of one or more test compounds on the vesicular transport of a probe substrate. In most cases a fluorescent probe substrate is included. Kits contain all reagents and solutions necessary to conduct the drug-transporter interaction assay of need.

Application

The PREDIVEZTM Vesicular Transport Kit is a simple and powerful tool to investigate drug transporter interactions. It provides information on any interaction between the ABC transporter and the drug candidate that would affect the transport of the fluorescent or radiolabeled or cold.

PREDIVEZTM vesicular transport kits are available in three sizes 3, 6 or 9 compound sizes. The kits contain the sufficient amount of reagents and membrane preparations needed for the testing of 3 compounds per 96-well plate. Each kit is accompanied by a CD that includes the assay protocol, an Excel spreadsheet with a data processing template, SDS and the inhibition curves with reference compounds.

Physical form

Supplied as frozen membrane vesicles, containing 5 mg/ml membrane protein, labeled with volume, catalog number (transporter), date of production, protocols and necessary reagents sufficent for the analysis of 3, 6, or 9 test compounds

Legal Information

Distributed for SOLVO Biotechnology, Inc.

Related product

pictograms

Health hazardCorrosion

signalword

Danger

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Met. Corr. 1 - Repr. 1A - Skin Corr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Márton Jani et al.
Journal of pharmaceutical sciences, 100(1), 94-97 (2010-06-25)
Ivermectin is an antiparasitic drug frequently administered to humans. It has a limited brain exposure that is attributed to the efflux activity of ABCB1/Abcb1. ABCG2/Abcg2 is also a major transporter present in most pharmacologically important barriers. However, interaction of ivermectin
Albert Mennone et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(10), 1673-1678 (2010-07-06)
Breast cancer resistance protein (Bcrp) is a member of the ATP-binding cassette membrane transporter family, which is expressed apically in liver, kidney, and intestine epithelium. Recent reports suggest that in addition to xenobiotics, porphyrins, and food toxins, Bcrp can also
Márton Jani et al.
Biological & pharmaceutical bulletin, 32(3), 497-499 (2009-03-03)
The pharmacokinetics of sulfasalazine, an anti-inflammatory drug is influenced by ATP-binding cassette G2 (ABCG2) (breast cancer resistance protein (BCRP), mitoxantrone resistance protein (MXR)) both in vitro and clinically. Due to its low passive permeability, the intracellular concentration of sulfasalazine is
E Kis et al.
Annals of the rheumatic diseases, 68(7), 1201-1207 (2008-04-10)
Earlier publications have suggested a possible role for the efflux transporter breast cancer resistance protein (BCRP) in acquired resistance to disease-modifying antirheumatic drugs (DMARDs) such as leflunomide and its metabolite A771726 (teriflunomide). However, there is no direct evidence that BCRP
Kumie Kage et al.
International journal of cancer, 97(5), 626-630 (2002-01-25)
Breast cancer resistance protein (BCRP) is a half-molecule ABC transporter highly expressed in mitoxantrone-resistant cells. In our study we established PA317 transfectants expressing Myc-tagged BCRP (MycBCRP) or HA-tagged BCRP (HABCRP). The exogenous BCRP protein migrated as a 70-kDa protein in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service